Market Newsdesk

NEVE ILAN, Israel, April 02, 2021 (GLOBE NEWSWIRE) — NANO-X IMAGING LTD (NASDAQ: NNOX) (“Nanox” or the “Company”), an innovative medical imaging technology company, announced today that its single-source Nanox.ARC digital x-ray technology has received 510(k) clearance from the US Food and Drug Administration (the “FDA”).

“Obtaining 510(k) clearance from the FDA for our single-source Nanox.ARC digital x-ray is a significant step forward along our US regulatory pathway,” stated Ran Poliakine, Chairman and Chief Executive Officer of Nanox. “We remain on track to commence system shipments in the fourth quarter of 2021 and the first quarter of 2022 with the goal of finalizing deployment of the initial 15,000 Nanox.ARC systems by the end of 2024.”   

“We believe we are well positioned to achieve our goal of democratizing medical imaging and expanding the market to the roughly two-thirds of the world’s population who currently have limited or no meaningful access to imaging or the preventative screening that it offers,” Mr. Poliakine concluded.   

The Company remains on track and expects to submit a 510(k) application to the FDA for its multi-source Nanox.ARC and the Nanox.CLOUD in 2021. If cleared, the multi-source Nanox.ARC will be the Company’s commercial imaging system that it expects to deploy broadly across the globe.

About Nanox:

Nanox, founded by the serial entrepreneur Ran Poliakine, is an Israeli corporation that is developing a commercial-grade digital X-ray source designed to be used in real-world medical imaging applications. Nanox believes that its novel technology could significantly reduce the costs of medical imaging systems and plans to seek collaborations with world-leading healthcare organizations and companies to provide affordable, early detection imaging service for all. For more information, please visit www.nanox.vision.

Forward-Looking Statements:

This press release may contain forward-looking statements that are subject to risks and uncertainties. All statements that are not historical facts contained in this press release are forward-looking statements. Such statements include, but are not limited to, any statements relating to the initiation, timing, progress and results of Nanox’s research and development, manufacturing and commercialization activities with respect to its X-ray source technology and the Nanox.Arc. In some cases, you can identify forward-looking statements by terminology such as “can,” “might,” “believe,” “may,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,” “should,” “could,” “expect,” “predict,” “potential,” or the negative of these terms or other similar expressions. Forward-looking statements are based on information Nanox has when those statements are made or management’s good faith belief as of that time with respect to future events, and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking statements. Factors that could cause actual results to differ materially from those currently anticipated include: risks related to business interruptions resulting from the COVID-19 pandemic or similar public health crises could cause a disruption of the development, deployment or regulatory clearance of the Nanox System and adversely impact our business; Nanox’s ability to successfully demonstrate the feasibility of its technology for commercial applications; Nanox’s expectations regarding the necessity of, timing of filing for, and receipt and maintenance of, regulatory clearances or approvals regarding its X-ray source technology and the Nanox.Arc from regulatory agencies worldwide and its ongoing compliance with applicable quality standards and regulatory requirements; Nanox’s ability to enter into and maintain commercially reasonable arrangements with third-party manufacturers and suppliers to manufacture the Nanox.Arc; the market acceptance of the Nanox.Arc and the proposed pay-per-scan business model; Nanox’s expectations regarding collaborations with third-parties and their potential benefits; and Nanox’s ability to conduct business globally, among others. Except as required by law, Nanox undertakes no obligation to update publicly any forward-looking statements after the date of this press release to conform these statements to actual results or to changes in Nanox’s expectations.

Contacts:

Investors

Itzhak Maayan
Nanox Imaging
[email protected]

Bob Yedid
LifeSci Advisors
646-597-6989
[email protected]

Media

Alona Stein
ReBlonde for Nanox
[email protected]

Manchester, UK, April 02, 2021 (GLOBE NEWSWIRE) — Owning a winning racehorse is a dream that so many racing enthusiasts have, yet many do not achieve due to a lack of knowledge, investment opportunities, or connections. Now, thanks to the vision and passion of three brothers from Manchester who followed their childhood dream, being part of the industry and owning a winner could be possible.

Dooley Thoroughbreds
was set up by Mark, David, and James Dooley. Although not from a traditional horse racing background, their childhoods were spent enthralled by the industry. Mark trained as a jockey, David became an expert at reading form and picking out winners, and James visited just about every racecourse in the country.

As time went on, careers and life did too, but their love of horse racing never faded. This love of the industry united them, and every time they met, they talked about going into ownership and joining syndicates.

In 2019, the Dooley brothers took the leap. All three had extensive knowledge of the industry and had saved up the capital to go into ownership. Just a year or so on, this leap has been repaid tenfold, with the brothers having winning horses at the likes of The Galway Mie, Ahonoora, The Lartigue Hurdle and more.

So how can you follow in the footsteps of the Dooley brothers and go into racehorse ownership? Here’s their story of how they did it, and how they offer a few select places within their racing syndicate for prospective owners:

1. How to become a racehorse owner

For the Dooley brothers, racehorse ownership was always something they had wanted to explore. They didn’t do it to make money, but instead to follow a family-interest that united everybody from partners and wives to nephews and nieces.

Their opportunity came about by a chance meeting. Bart O’Sullivan was a well-respected and knowledgeable racehorse owner who had horses trained in Ireland by Adrian McGuiness. Bart introduced the Dooley brothers to Adrian, and their clear passion for the sport compelled Adrian to work with them.

Whilst it was a chance meeting for Mark, David and James Dooley, it never hurts to explore opportunities with owners and trainers who you may know in the industry, and consider joining a syndicate that can offer you that chance to get involved.

2. The investment required to become an owner of a winning horse

For newcomers and experienced pros, owning a horse isn’t a one-man job. Partnerships and syndicates exist so that a small group of enthusiasts can invest in purchasing a horse, covering the cost of training, housing, vets’ fees etc.

The Dooley brothers decided to invest in three horses with Adrian McGuiness called Saltonstall, Sirjack Thomas and Kasbah. These first three horses would all win races, notably Saltonstall, who captured the £120k Galway mile at the Galway Festival in 2019.

3. Sharing the opportunity, through the Dooley Thoroughbreds horse racing syndicate

The Dooley Brothers haven’t looked back since 2019. With an eye for detail and top tier connections, they have become one of the most influential and sought-after syndicates in the UK. Where they differ from others is that their family-run, close-knit community is focused on making you a big part of the ownership process.

Joining the Dooley Thoroughbreds horse racing syndicate means you are involved in the experience from start to finish. You are consulted about the decisions made on the horse and its racing career, you can freely visiting the stables, have regular training updates, a share of the prize money and most importantly, enjoy the thrill of going racing and making life long memories.

Considering becoming a racehorse owner through the Dooley Thoroughbreds horse racing syndicate?

The Dooley brothers stick to their roots and prefer their syndicates to be at a small and manageable size. They remain personally invested, both mentally and financially, and as such they don’t offer many places within their syndicate. However, with more Dooley Thoroughbred winners expected over the next few years, they are happy to hear from potential partners. You can learn more via their website.

More information:

Dooley Thoroughbreds was set up in 2019 by three brothers who have had a lifelong passion for horse racing. They had a desire to create memorable days out for family and friends, and a chance to get together as a family to unite behind a shared interest. Now, thanks to their success, they make racehorse ownership a reality for others with their Dooley Thoroughbreds horse racing syndicate. Find out more by visiting their website: https://www.dooleythoroughbreds.co.uk/.   

Follow Dooley Thoroughbreds on:

Twitter

Facebook

YouTube

https://thenewsfront.com/dooley-thoroughbreds-horse-racing-syndicate-a-huge-uk-success-story/

Dooley Thoroughbreds

https://www.dooleythoroughbreds.co.uk/

[email protected]

LOS ANGELES, April 02, 2021 (GLOBE NEWSWIRE) — The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.  Investors have until the deadlines listed below to file a lead plaintiff motion.

Investors suffering losses on their investments are encouraged to contact The Law Offices of Frank R. Cruz to discuss their legal rights in these class actions at 310-914-5007 or by email to [email protected].

Neptune Wellness Solutions Inc. (NASDAQ: NEPT)
Class Period: July 24, 2019 – February 16, 2021
Lead Plaintiff Deadline: May 17, 2021

The complaint filed alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) the cost of Neptune’s integration of the assets and operations acquired in the SugarLeaf Acquisition would be larger than the Company had acknowledged, placing significant strain on the Company’s capital reserves; (2) accordingly, it was reasonably foreseeable that the company would need to conduct additional stock offerings to raise more capital; and (3) as a result, Defendants’ statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.

BELLUS Health Inc. (NASDAQ: BLU)
Class Period: September 5, 2019 – July 5, 2020
Lead Plaintiff Deadline: May 17, 2021

The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, the complaint alleges that Defendants knew, but failed to disclose, that while BLU-5937’s “high selectivity” contributed to the drug causing little to no taste alteration in chronic cough patients, that high selectivity also contributed to the drug potentially being less efficacious and thus likely not be able to meet the primary endpoint of the Company’s Phase 2 trial.

Lordstown Motors Corp. (NASDAQ: RIDE)
Class Period: August 3, 2020 – March 17, 2021
Lead Plaintiff Deadline: May 17, 2021

The complaint filed alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) the Company’s purported pre-orders were non-binding; (2) many of the would-be customers who made these purported pre-orders lacked the means to make such purchases and/or would not have credible demand for Lordstown’s Endurance; (3) Lordstown is not and has not been “on track” to commence production of the Endurance in September 2021; (4) the first test run of the Endurance led to the vehicle bursting into flames within 10 minutes; and (5) as a result, Defendants’ statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.

CytoDyn, Inc. (OTC: CYDY)
Class Period: March 27, 2020 – March 9, 2021
Lead Plaintiff Deadline: May 17, 2021

The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements touting Leronlimab as a potential treatment for COVID-19 to pump up the CytoDyn’s stock price while executives aggressively sold their shares. The complaint also alleges that CytoDyn engaged in a wrongful scheme whereby Iliad and other Fife entities operated as an unregistered securities dealer for CytoDyn.

Follow us for updates on Twitter: twitter.com/FRC_LAW.

To be a member of these class actions, you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action. If you wish to learn more about these class actions, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Frank R. Cruz, of The Law Offices of Frank R. Cruz, 1999 Avenue of the Stars, Suite 1100, Los Angeles, California 90067 at 310-914-5007, by email to [email protected], or visit our website at www.frankcruzlaw.com.   If you inquire by email please include your mailing address, telephone number, and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contacts

The Law Offices of Frank R. Cruz, Los Angeles
Frank R. Cruz, 310-914-5007
[email protected]
www.frankcruzlaw.com